Better Heart Health Without Surgery: R3 Stem Cell Therapy

Free Download: Stem Cell Therapy for Heart Disease

Disclaimer:

The information provided by R3 Stem Cell is for educational purposes and is not a substitute for professional medical advice, diagnosis, or treatment. Individual results may vary and are not guaranteed. The FDA considers stem cell therapy experimental at this point.

Any claims made on this website refer to procedures performed OUTSIDE of the USA. R3 Stem Cell has clinics in Mexico, Philippines, South Africa, Turkey, India, Pakistan.

Please fill out the form below to receive the guide

I agree to receive marketing messages from the business.Message and data rates may apply.Message frequency varies. Text HELP for help. Text STOP to unsubscribe.

Guide to Stem Cell and Exosome Therapy for Heart Disease

Every day, R3 Stem Cell receives inquiries worldwide from individuals asking if stem cell therapy can help for heart failure. Spoiler alert: It can help a lot! In this guide, we’ll go through the basics of how stem cells and exosomes work for heart disease, the latest research, and what to expect with a regenerative procedure.

Conventional treatments for heart disease are often not able to stop disease progression. For those who desire improved heart function along with an enhanced quality of life, failure with conventional treatments is disappointing and occurs all too often.

Stem cell therapy for heart disease is turning out to be an excellent opportunity for individuals to achieve meaningful long-term results. Let’s dig in!

A Significant Global Issue

Heart failure (HF) is a common, expensive, lethal, and disabling condition. Its prevalence in industrialized nations has reached epidemic proportions (e.g. 6.5 million in the USA), and continues to rise as the population ages.

Despite significant advances over the last three decades, the prognosis of patients hospitalized with heart failure remains poor, and the 5-year mortality approaches 50%. Therefore, heart failure constitutes a major public health problem worldwide, a leading cause of morbidity and mortality, and an increasing burden on healthcare systems around the globe.

Living with heart disease? Stem cell therapy shows promising results for heart function. Call R3 Stem Cell at (844) GET-STEM.

Traditional Treatments

While the existing therapies for ischemic heart disease lower the early mortality rates, prevent additional damage to the heart muscle, and reduce the risk of further heart attacks, most of the patients are likely to have worse quality of life including frequent hospitalizations.

Heart diseases are the major cause of mortality worldwide, with approximately 20 million people aged 30–70 years dying from the disease every year. At present, the disease tends to affect younger individuals. The available treatments include heart transplantation, surgical interventions, and pharmaceutical therapies. Surgical treatment is typically associated with complications and generally is not recommended unless the condition is severe. Even if the patients survive and the condition improves, a longterm maintenance treatment is necessary.

Therefore, there is an ultimate need for a treatment to improve the clinical conditions by either replacing the damaged heart cells and/or improving cardiac performance. Thus, the cardiac tissue regeneration with the application of stem cells, or their exosomes, may be an effective therapeutic option.

Ready for a consultation? Connect with R3 Stem Cell at (844) GET-STEM.

Stem Cell Therapy for Heart Disease

Human umbilical cord mesenchymal stem cells (HUCMSCs) offer a relatively safe and effective alternative therapy for heart diseases. HUC-MSCs have been shown to treat and relieve various cardiovascular diseases, including myocardial infarction, heart failure, myocardial ischemia, and myocarditis.

Mesenchymal stem cells promote cardiac tissue regeneration and angiogenesis, inhibit inflammation, and significantly reduce infarct size and mortality. Also, the transplantation of HUC-MSCs improves the New York Heart Association functional class and the results of the Minnesota Living with Heart Failure Questionnaire and 6-min walk test, significantly improving patients’ quality of life.

In 2012, Duckers and co-workers were the first reporting the feasibility, safety and beneficial effects, including reduced myocardial scar formation and improved perfusion, of intracoronary infused adipose tissue-derived mesenchymal stem cells in a randomized, placebo-controlled clinical trial.

The transplanted stem cells enhanced the local contractile function of the myocardium, reduced the necrotic infarcted area, and increased ejection fraction. The long-term follow-up found that the induction of blood vessel formation was also an essential part of heart repair after injury. Importantly, mesenchymal stem cells exert anti-inflammatory effects. In summary, mesenchymal stem cells perform a therapeutic function in heart-related diseases by the following mechanisms:

enhancing the proliferation of cardiomyocytes to improve heart function,

enhancing angiogenesis and blood supply,

improvement of cardiac performance by inhibiting myocardial cell death,

anti-inflammatory and anti-fibrotic activity through paracrine effects, and

regulating the expression levels of miRNAs, lncRNAs, and circRNAs involved in cardiac repair.

Recent results of the RIMECARD study by Bartolucci et al. in human subjects using umbilical cord-derived MSCs as potential heart failure therapy are quite encouraging. The patients had stable heart failure (HF), with a reduced ejection fraction of less than 40.

Although the sample size was small (15 controls and 15 HF patients treated with UC-MSCs) to establish either safety or efficacy, the echocardiographic and cardiac MRI evaluations demonstrated improvements in ejection fraction, starting at 3 months, and persisting through 12 months. The patients treated with placebo did not improve in either left ventricular ejection fraction or clinical functional class. As indicated by the authors, it is tempting to speculate that the robust paracrine secretion of various factors, including hepatocyte growth factor, might play an important role in mediating the therapeutic effects of the UC-MSCs.

The RIMECARD trial (Randomized Clinical Trial of Intravenous Infusion Umbilical Cord Mesenchymal Stem Cells on Cardiopathy) was a phase 1/2, randomized, doubleblind, placebo-controlled clinical trial. The study was conducted in Chile and participants were enrolled in a 1:1 randomization to intravenous infusion of umbilical cord mesenchymal stem cells or placebo.

There were no acute adverse events associated with the infusion and the intervention resulted in a significant improvement in left ventricular function (18%), functional status, and quality of life.

Lunde et al. studied the activity capacity and quality of life in 50 patients with myocardial infection following stem cell injection in 2007; activity capacity and oxygen consumption were significantly higher in the stem cell group compared to the control group.

A study called the POSEIDON trial, published in 2012, was the first study to compare autologous and allogeneic MSCs in patients with ischaemic HF. In this randomized Phase I/II study, three doses of autologous or allogeneic BM-MSCs (20, 100, and 200 million stem cells) were given transendocardially in 30 subjects. At 12 months, both allogeneic and autologous MSCs reduced scar size by 33%.

Allogeneic cells (donor), however, appeared to be more effective in that they significantly reduced left ventricle end-diastolic volume (LVEDV) whereas autologous cells did not. POSEIDON was important because it was the first trial to support the concept that allogeneic MSCs may be superior to autologous MSCs.

Compared with bone marrow mesenchymal stem cells, however, umbilical cord mesenchymal stem cells offer several advantages, including wide availability, easier isolation, higher proliferative capacity and less cellular aging. Importantly, there is evidence that UCMSCs are more potent than BM-MSCs (since they are derived from a much younger organism).

Another study conducted in chronic systolic heart failure by Zhao et al. evaluated the effectiveness of Umbilical cord-MSCs through intracoronary transplantation. Among the 30 recipients, 29 patients had no adverse reactions, heart palpitations, chest pain, chest tightness, dyspnoea or other symptoms, while one experienced chest discomfort. The cardiac left ventricle ejection fraction and 6-min walking distance were significantly improved at the six month follow up.

The TRIDENT study adds to a growing body of research on the safety of allogeneic hMSCs in ICM and addresses the issue of dosage in cell-based therapies, providing additional evidence of a direct relationship between cell dose and clinical efficacy.

The TRIDENT study was a randomized, double-blinded comparison of two doses of allogeneic mesenchymal stem cells delivered to patients with ischemic cardiomyopathy. The TRIDENT study demonstrated that mesenchymal stem cells are clinically effective in reducing scar size and improving cardiac function. An intriguing finding of this study was that ejection fraction was improved only in the 100 million stem cell group, suggesting that the higher dose provides a greater benefit to cardiac function than the lower dose.

Heart failure patients: Stem cells may help create new blood vessels and reduce scarring. Call R3 Stem Cell at (844) GET-STEM.

How do Stem Cells and Exosomes Act in the Body?

Stem cells and exosomes act in the body through several mechanisms. They do NOT become part of a patient’s DNA, which means they do not engraft into the person’s existing cells.

They act through:

Angiogenesis

provokes formation of new blood vessels.

Reduce inflammation

Heart disease is associated with significant inflammation, and the regenerative biologics reduce it nicely.

Immune system modulation

the stem cells and exosomes modulate the immune system very differently than steroids. Instead of blanketly suppressing the immune system, the regenerative biologics tamp down the harmful processes while amping up the beneficial ones. This includes ramping up production of several helpful growth factors and cytokines, while tamping down harmful ones.

Cellular signaling

the biologics are able to perform “cell to cell” communication. This promotes recipient cells to proliferate their growth factor production, protein production and regenerate nerve tissues that are damaged.

Prevent cell death

most cells have a timed death, where they are only allowed to live a certain length of time. This is called apoptosis. The regenerative biologics allow normally functioning cells (i.e. neuron cells) to live longer, and spare them from the pre-programmed.

Preventing scar tissue

Once that scar tissue forms, it becomes nonfunctional. Stem Cells and exosomes are great at preventing scar tissue (anti-fibrosis).

Stem Cells can also release a huge variety of molecules into the extracellular environment. These molecules, which include extracellular vesicles (exosomes), lipids, free nucleic acids, and soluble proteins, exert crucial roles in repairing damaged tissue. Along with offering stem cells for treatment of psoriasis, R3 Stem Cell includes stem cell exosomes, which are a type of extracellular vesicle participating in extensive cell to cell communication for ovarian tissue repair and regeneration.

The stem cells administered by R3 are not the ones that become part of a patient’s DNA. The administered mesenchymal stem cells are not specifically designed to replace damaged and lost epithelial cells, but rather coordinate immune system modulation.

R3 Stem Cell’s heart disease protocol includes both stem cells and exosomes for maximum benefit. Details at (844) GET-STEM.

Where do the stem cells and exosomes come from?

R3 Stem Cell’s regenerative biologics originate from umbilical cord tissue that has been donated after a scheduled c-section. No baby (or mother) is harmed during the c-section procedure. The umbilical cord tissue is normally discarded, but if the mother passes screening test then the umbilical cord is immediately sent to the lab.

The lab carefully processes the umbilical cord to generate large amounts of stem cells and exosomes that are of the highest quality possible. The lab team consists of multiple PhD’s working in ISO Certified, cGMP compliant clean rooms to ensure quality assurance that exceeds USA FDA standards. The proprietary production process combines the highest potency, safety and affordability for providers to confidently offer exosome procedures.

Millions of dollars have been invested into the pharmaceutical grade production of the biologics including first rate clean rooms, bioreactors, nano-particle tracking analyzers, cytometers, PCR, tangential flow machines and real time environmental monitoring. The quality assurance testing complies with screening and testing stan¬dards consistent with the American Association of Tissue Banks, cGMP standards, FDA regulations and the highest level of any regulatory agency globally.

Ask about therapy options for joint pain due to RA: (844) GET-STEM.

Stem Cell Derived Exosomes

R3 Stem Cell’s Centers of Excellence globally include umbilical cord stem cell derived exosomes with umbilical cord stem cells to provide enhanced results. Exosomes are lipid bound vesicles (acellular) produced by cells which contain a plethora of growth factors, cytokines, mRNA and other proteins.

They are exceptionally helpful in cell to cell communication, and very effective for reducing inflammation when they become ingested by their recipient cell. They act as shuttles to send nucleic acids and proteins to other cells, in this way, allowing cell-tocell communication and transporting molecules among both close and distant cells. In general, these released proteins are important regulators of intracellular information.

Exosomes could be the mediators of many stem cell-associated therapeutic activities. Considering they are 100 times smaller than stem cells, they do not have any issues passing through the blood-brain-barrier to reach the brain from the bloodstream.

Exosomes can be derived from many different types of stem cells including umbilical cord, cardiospherederived cells, cardiac stem cells, embryonic, induced pluripotent, mesenchymal and endothelial progenitor cells. They can carry and deliver mRNAs, miRNAs and proteins to the injured heart muscle and play a significant role in resident cardiac stem cell activity, cardiomyocyte proliferation, beneficial cardiac remodeling, apoptosis reduction, angiogenesis, antiinflammatory response and a decrease in infarct size. The advantages for effective exosome therapy include the cell free component, long-term stability and low or no immune response.

Is stem cell therapy safe?

After a decade of performing over 24,000 stem cell procedures worldwide, R3 knows that the regenerative procedures are safe. The quality control employed during the stem cell production is second to none, and the side effects R3 sees are usually mild to moderate and temporary.

They may include itching, dizziness, lightheadedness, low grade fever, chills, headache, nausea. These are typically temporary. If a patient has an allergic reaction to the multivitamin or a preservative, all of R3’s Centers have the medications to resolve it quickly.

One of the questions we get asked a lot is, “Will the stem cells get rejected?” The answer is NO.

MSCs do not express major histocompatibility complex (MHC) antigens of the class II subtype and contain low levels of MHC molecules of the class I subtype. MSCs also lack the co-stimulatory molecules essential for immune detection, including CD40, CD80, and CD86.

Therefore, MSCs generally have low immunogenicity and can avoid immune rejection by the recipient, which serves as the foundation for their successful application without needing to match the donor to the recipient. Scientists call this being “immunologically privileged”.

Another question often asked is “Is there a chance of a tumor forming?” Once again the answer is NO. The mesenchymal stem cells and exosomes used during treatment have never been shown to have tumor forming potentials. In fact, they have been shown to be anti-tumor forming.

Stem cell therapy might be right for you. Find out during a no-cost consultation with R3 Stem Cell doctors. Call (844) GET-STEM today.

Treatment Protocol

For the past decade, R3 has been successfully treating patients with stem cell and exosome therapies with injection, infusion, intranasal, intrathecal and nebulizer procedures.

For heart disease, R3’s providers use between one and two million stem cells per kilogram (depending on patient weight). In addition, billions of stem cell exosomes and platelet rich plasma therapy (PRP) are included at no cost.

R3 Stem Cell’s heart disease treatment protocol includes an IV therapy combining mesenchymal stem cells and exosomes, along with a multivitamin IV as well. Safety is paramount with the biologics products being rigorously tested prior to use, and expert providers managing each treatment as if you are a family member! This is why we don’t perform the heart catheterization application, as patients in some studies have suffered significant adverse events as a result.

Why does R3 Stem Cell use donor tissue for its stem cells?

Although autologous (your own) stem cells provide significant advantages, allogeneic (donor) stem cells have more advantages. First of all, autologous MSCs need a long time to culture and expand, which limits its application in treatment, while allogeneic stem cells can be obtained and expanded more quickly, thus avoiding the delay of time window.

Second, age is a factor that affects the physiological characteristics of MSCs. Studies have shown that stem cells from elderly donors have decreased proliferation and differentiation ability. This means they are less in number and less effective!

Affordability
R3's Experience

Stem cell therapy for psoriasis may be the key step to completely changing a person’s quality of life, and we want to make it affordable for as many individuals as possible. Our global volume has allowed us to keep our patient cost as low as possible.

Unfortunately, stem cell clinics in Colombia, China and Panama charge over $20,000 USD for psoriasis treatment. How are individuals supposed to budget for that?? R3 Stem Cell’s fees are typically less than half that for full treatment, which also includes free exosomes, PRP and a multivitamin infusion!

For the past decade, R3 Stem Cell’s Centers globally have performed over 24,000 regenerative procedures in six countries. Patient satisfaction across all conditions treated is very high, at 85%. R3 has treated many patients with varying types of heart disease.

R3 combines safety, effectiveness and affordability for the therapies. Internationally, the Intellicell is used, which is culturing the most active mesenchymal stem cells to create the “smartest” stem cell in the world!

R3 Stem Cell offers free consultations for individuals to discuss whether regenerative therapy is indicated for your heart disease. Simply call (844) GET-STEM to schedule yours!

References

Peruzzi et al, State of the Art on the Evidence Base in Cardiac Regenerative Therapy: Overview of 41 Systematic Reviews, Hindawi Publishing Corporation BioMed Research International Volume 2015, Article ID 613782, 7 pages http://dx.doi. org/10.1155/2015/613782
Muller et al, Stem Cell Therapy in Heart Diseases – Cell Types, Mechanisms and Improvement Strategies, Cell Physiol Biochem 2018;48:2607-2655.
Xie et al, What is the impact of human umbilical cord mesenchymal stem cell transplantation on clinical treatment? Xie et al. Stem Cell Research & Therapy (2020) 11:519 https://doi. org/10.1186/s13287-020-02011-z
Bartolucci J, Verdugo FJ, González PL, Larrea RE, Abarzua E, Goset C, Rojo P, Palma I, Lamich R, Pedreros PA, Valdivia G, Lopez VM, Nazzal C, Alcayaga-Miranda F, Cuenca J, Brobeck MJ, Patel AN, Figueroa FE, Khoury M. Safety and efficacy of the intravenous infusion of umbilical cord mesenchymal stem cells in patients with heart failure: a phase 1/2 randomized controlled trial (RIMECARD trial [randomized clinical trial of intravenous infusion umbilical cord mesenchymal stem cells on cardiopathy]). Circ Res. 2017;
Terashvili et al, Stem Cell Therapies in Cardiovascular Disease, J Cardiothorac Vasc Anesth. Author manuscript; available in PMC 2020 January 01.
Mostafavian et al, Effect of Stem Cell Therapy on Patients’ Quality of Life in Heart Failure with Reduced Ejection Fraction, Journal of Medicine and Life Vol. 11, Issue 4, October-December 2018, p_p_._ _3_5_9_–3_6_4_ _
Bolli et al, Cell therapy in patients with heart failure: a comprehensive review and emerging concepts , Cardiovascular Research (2022) 118, 951–976, doi:10.1093/cvr/cvab135
Chen et al, The application of umbilical cord-derived MSCs in cardiovascular diseases, J Cell Mol Med. 2021;25:8103–8114.
Florea et al, Dose Comparison Study of Allogeneic Mesenchymal Stem Cells in Patients with Ischemic Cardiomyopathy (The TRIDENT Study), Circ Res. Author manuscript; available in PMC 2022 January 08.
Tompkins et al, Comparison of Mesenchymal Stem Cell Efficacy in Ischemic Versus Nonischemic Dilated Cardiomyopathy, J Am Heart Assoc. 2018;7:e008460. DOI: 10.1161/JAHA.117.008460.)
Yamada et al, Cell Therapy Improves Quality-of-Life in Heart Failure: Outcomes From a Phase III Clinical Trial, Stem Cells Translational Medicine, 2024, 13, 116–124 https://doi. org/10.1093/stcltm/szad078 Advance access publication 24 November.

About R3 Stem Cell

David Greene, MD, PhD, MBA, Founder/CEO

R3 Stem Cell offers treatments that bring patients hope and options. Hope that surgery can be avoided, and tissue injury can be repaired with patients being able to get back to desired activities.

Founder and CEO David Greene, MD, PhD, MBA writes extensively on regenerative medicine and gives many seminars worldwide on a regular basis. With over forty Centers of Excellence globally, R3 is at the forefront of regenerative therapies.

R3’s Centers have successfully performed over 25,000 regenerative procedures to date. Call today for your free consultation (844) GET-STEM!

No portion of this Document may be reproduced without the Express Written Consent of R3 Stem Cell.

Disclaimer:

This guide’s education does not constitute medical advice. The USA FDA considers stem cell therapy experimental. Any claims made in the Guide refer to procedures performed outside the USA.

Brand Ambassador Gallery

The USA stem cell leader offers procedures in

7 Countries including:

UNITED STATES

MEXICO

PHILIPPINES

SOUTH AFRICA

PAKISTAN

INDIA

TURKEY

SUCCESS STORIES

*Outcomes will vary between individuals. No claims are being made with regenerative therapies. The FDA considers stem cell therapy experimental. See our THERAPY COMMITMENT HERE.

Actor Ryan Paevey Receives Stem Cell Therapy at R3 Stem Cell

Regenerative Therapy for Kidney Failure – It Changed My Life!

Journey Lead Singer Arnel Pineda Receives Stem Cell Treatment at R3

R3 STEM CELL MASTER CLASS

Learn everything you need to know about the ever expanding field of regenerative medicine in this 8 part series that includes over four hours of entertaining content!

R3 STEM CELL INTERNATIONAL

R3 Stem Cell International includes 45 clinics in 7 countries. These Centers of Excellence treat all types of conditions with safe, effective protocols by expert stem cell physicians.

FREE STEM CELL CONSULTATION

R3 Stem Cell offers a no cost consultation to see if you or a loved one is a candidate for regenerative cell therapies including cytokines, growth factors, exosomes, and stem cells.

PROVIDER PARTNERSHIP

The R3 Partnership Program offers providers an all-in-one regenerative practice program including marketing, consultations and booked procedures!

FREE WEBINAR: AVOID SURGERY WITH STEM CELL THERAPY

ABOUT US

The information provided by R3 Stem Cell is not a substitute for professional medical advice, diagnosis, or treatment. Individual results may vary and only your medical professional can explain all the risks and potential benefits of any therapy based on your circumstances. R3 Stem Cell does not recommend or endorse any specific tests, products, procedures, opinions, or other information that may be mentioned on this website. Reliance on any information provided by R3 Stem Cell, its employees, others appearing on this website at the invitation of R3 Stem Cell, or other visitors to the website is solely at your own risk. R3 Stem Cell is not responsible for the outcome of your procedure. The FDA considers stem cell therapy experimental at this point.